TMCI

+ Watchlist + Portfolio

Treace Medical Concepts, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.56
52-Week Range: $1.17 – $7.78
Market Cap: $290.05M
P/E (TTM): —
EPS (TTM): -0.92
Dividend Yield: —

Advanced Metrics

Price/Book: 4.28
PEG Ratio: —
Return on Equity: -71.99%
Return on Assets: -17.33%
Gross Margin: 79.45%
Operating Margin: -32.97%
Profit Margin: -28.99%
Current Ratio: 2.90
Debt/Equity: 1.08
Total Debt: $73.05M
Free Cash Flow: $-6.25M
Revenue Growth: -4.20%
Earnings Growth: —
Enterprise Value: $323.99M

TMCI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$141.84M	$187.12M	$209.36M	$212.69M
Cost of Revenue	$25.53M	$35.18M	$41.09M	$42.94M
Gross Profit	$116.31M	$151.94M	$168.26M	$169.75M
Research & Development	$13.58M	$15.44M	$20.59M	$20.28M
Selling, General & Admin	$137.57M	$187.93M	$203.36M	$203.62M
Operating Expenses	$151.15M	$203.37M	$223.95M	$223.91M
Operating Income	-$34.84M	-$51.43M	-$55.69M	-$54.15M
EBITDA	-$36.28M	-$39.01M	-$42.07M	-$43.06M
Pretax Income	-$42.81M	-$49.53M	-$55.74M	-$59.00M
Net Income	-$42.81M	-$49.53M	-$55.74M	-$59.00M
Diluted EPS	-0.77	-0.81	-0.90	-0.93
Diluted Shares	55.28M	60.85M	62.11M	63.27M

TMCI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.47M	$12.98M	$11.35M	$10.71M
Receivables	$29.20M	$38.06M	$40.80M	$42.16M
Inventory	$19.33M	$29.25M	$39.26M	$36.03M
Current Assets	$133.40M	$198.36M	$161.40M	$132.05M
Total Assets	$159.02M	$251.91M	$217.09M	$190.58M
Current Liabilities	$30.25M	$45.03M	$34.92M	$30.64M
Long-Term Debt	$52.71M	$53.01M	$53.31M	$55.58M
Total Debt	$68.59M	$70.30M	$69.65M	$71.86M
Total Liabilities	$98.50M	$113.97M	$104.20M	$103.25M
Retained Earnings	-$84.72M	-$134.25M	-$189.99M	-$248.99M
Shareholders' Equity	$60.53M	$137.94M	$112.89M	$87.33M
Working Capital	$103.16M	$153.33M	$126.48M	$101.42M
Net Debt	$33.24M	$40.03M	$41.96M	$46.62M

TMCI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$30.65M	-$34.58M	-$37.17M	-$15.97M
Capital Expenditure	-$14.84M	-$11.46M	-$11.59M	-$13.52M
Free Cash Flow	-$45.49M	-$46.03M	-$48.76M	-$29.49M
Depreciation & Amortisation	$2.13M	$5.35M	$8.42M	$10.62M
Stock-Based Compensation	$8.11M	$17.35M	$30.60M	$33.82M
Investing Cash Flow	-$76.52M	-$81.30M	$35.38M	$13.25M
Financing Cash Flow	$20.81M	$109.38M	$160.00K	$2.08M
Dividends Paid	—	$0.00	$0.00	$0.00
Net Change in Cash	-$86.36M	-$6.49M	-$1.63M	-$642.00K

TMCI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$52.57M	$47.39M	$50.21M	$62.52M	$47.20M
Cost of Revenue	$10.68M	$9.63M	$10.51M	$12.12M	$9.79M
Gross Profit	$41.89M	$37.75M	$39.71M	$50.40M	$37.41M
Research & Development	$5.56M	$5.50M	$4.68M	$4.54M	$4.62M
Selling, General & Admin	$51.91M	$49.23M	$50.70M	$51.78M	$49.95M
Operating Expenses	$57.48M	$54.73M	$55.38M	$56.32M	$54.57M
Operating Income	-$15.58M	-$16.97M	-$15.68M	-$5.92M	-$17.17M
EBITDA	-$12.15M	-$13.50M	-$12.17M	-$5.24M	-$15.49M
Pretax Income	-$15.92M	-$17.40M	-$16.29M	-$9.39M	-$17.96M
Net Income	-$15.92M	-$17.40M	-$16.29M	-$9.39M	-$17.96M
Diluted EPS	-0.25	-0.28	-0.26	-0.15	-0.28
Diluted Shares	62.66M	63.01M	63.52M	63.86M	64.59M

TMCI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$13.37M	$8.05M	$7.69M	$10.71M	$9.54M
Receivables	$31.11M	$30.33M	$32.96M	$42.16M	$30.36M
Inventory	$37.94M	$42.40M	$41.42M	$36.03M	$36.37M
Current Assets	$149.44M	$147.60M	$138.00M	$132.05M	$123.47M
Total Assets	$205.85M	$206.44M	$196.59M	$190.58M	$184.10M
Current Liabilities	$33.18M	$41.90M	$40.91M	$30.64M	$34.49M
Long-Term Debt	$53.38M	$53.45M	$53.53M	$55.58M	$55.82M
Total Debt	$69.36M	$70.09M	$70.37M	$71.86M	$71.60M
Total Liabilities	$100.50M	$108.83M	$107.40M	$103.25M	$106.91M
Retained Earnings	-$205.91M	-$223.31M	-$239.60M	-$248.99M	-$266.95M
Shareholders' Equity	$105.34M	$97.61M	$89.19M	$87.33M	$77.19M
Working Capital	$116.26M	$105.70M	$97.09M	$101.42M	$88.98M
Net Debt	$40.05M	$46.52M	$47.64M	$46.62M	$48.05M

TMCI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$4.20M	-$3.05M	-$9.09M	-$8.03M	$7.24M
Capital Expenditure	-$3.54M	-$4.77M	-$2.81M	-$2.40M	-$3.06M
Free Cash Flow	$655.00K	-$7.82M	-$11.90M	-$10.42M	$4.18M
Depreciation & Amortisation	$2.46M	$2.58M	$2.78M	$2.81M	$899.00K
Stock-Based Compensation	$8.69M	$9.58M	$8.00M	$7.55M	$8.03M
Investing Cash Flow	-$1.89M	-$3.26M	$8.74M	$9.67M	-$7.82M
Financing Cash Flow	-$282.00K	$987.00K	-$10.00K	$1.38M	-$588.00K
Net Change in Cash	$2.02M	-$5.32M	-$366.00K	$3.02M	-$1.16M

Market Snapshot

About

Treace Medical Concepts, Inc. is a medical technology company focused on advancing the standard of care for the surgical management of bunion deformities. The company has developed the Lapiplasty 3D Bunion Correction system, a proprietary procedure and instrumentation platform.